Literature DB >> 20375379

Targeting an ultrasound contrast agent to folate receptors on ovarian cancer cells: feasibility research for ultrasonic molecular imaging of tumor cells.

Wu Xing1, Wang Zhigang, Hu Bing, Ran Haitao, Li Pan, Xu Chuanshan, Zheng Yuanyi, Li Ao.   

Abstract

OBJECTIVE: The purpose of the study was to synthesize and characterize folate-targeted microbubbles (MB(F)) as an ultrasound contrast agent and to evaluate their affinity to the folate receptor (FR) in vitro.
METHODS: Folate-targeted microbubbles were prepared by incorporating 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]-folate into the lipid membrane of microbubbles. The diameter and concentration of the MB(F) were determined by a cell counter and sizer. The MB(F), control microbubbles (MB(C)), and MB(F) with a free folic acid block-ade were tested for binding specificity to human ovarian carcinoma SKOV3 cells, which overexpress the FR, by microscopy and confocal imaging, respectively.
RESULTS: The basic physical characteristics of MB(F) were similar to those of MB(C). In the cell binding test, the adherence efficiency of MB(F) to the SKOV3 cells (mean +/- SD, 16 +/- 5 microbubbles per cell; P < .01) was significantly higher than that of MB(C) (0.7 +/- 0.4 microbubbles per cell) or MB(F) with the free folic acid blockade (0.7 +/- 0.6 microbubbles per cell).
CONCLUSIONS: Folate-targeted microbubbles showed high affinity to SKOV3 cells with FR overexpression. They are potentially useful for ultrasonic molecular imaging and treatment of FR-positive tumors and warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375379     DOI: 10.7863/jum.2010.29.4.609

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  6 in total

1.  Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non-small cell lung cancer patients.

Authors:  Xiaohong Zhang; Can Xiao
Journal:  Exp Ther Med       Date:  2018-05-23       Impact factor: 2.447

2.  Contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors.

Authors:  Jing-Jing Qiao; Jing Yu; Zhe Yu; Na Li; Chen Song; Man Li
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

3.  Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.

Authors:  Jaleh Barar; Vala Kafil; Mostafa Heidari Majd; Abolfazl Barzegari; Sajjad Khani; Mohammad Johari-Ahar; Davoud Asgari; George Coukos; George Cokous; Yadollah Omidi
Journal:  J Nanobiotechnology       Date:  2015-03-26       Impact factor: 10.435

4.  Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma.

Authors:  Shoubing Zhou; Xiu Zhang; Cailian Wang
Journal:  Oncotarget       Date:  2017-01-17

5.  Cyanine 5.5 conjugated nanobubbles as a tumor selective contrast agent for dual ultrasound-fluorescence imaging in a mouse model.

Authors:  Liyi Mai; Anna Yao; Jing Li; Qiong Wei; Ming Yuchi; Xiaoling He; Mingyue Ding; Qibing Zhou
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

6.  Bone morphogenetic protein and activin membrane-bound inhibitor suppress bone cancer progression in MG63 and SAOS cells via regulation of the TGF-β-induced EMT signaling pathway.

Authors:  Fengsong Liu; Kai Wang; Liang Zhang; Ya-Lin Yang
Journal:  Oncol Lett       Date:  2018-08-06       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.